Develops and commercializes living cell therapies for the field of regenerative medicine, which repairs damaged human tissue and enables the body to heal itself. It currently manufactures and markets Dermagraft, a bioengineered skin substitute that assists in restoring damaged tissue and supports the bodys natural healing process. Dermagraft has received premarket approval from the FDA for the treatment of diabetic foot ulcers.
WebsiteData as of Publication on
No. 187 (2011)